Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 13/20 | 0.42 |
| ▸ | CCNK | O75909 | 1/20 | 0.40 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | HTR7 | P34969 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3086715 | 1.00 | MAPK14 (0.42) | MAPK14CCNKCDK12CA2NPC1 | |
| SCHEMBL1175673 | 0.88 | MAPK14 (0.41) | MAPK14CCNKCDK12 | |
| SCHEMBL1175671 | 0.88 | MAPK14 (0.41) | MAPK14CCNKCDK12 | |
| SCHEMBL1175351 | 0.86 | MAPK14 (0.41) | MAPK14CCNKCDK12CA2NPC1 | |
| SCHEMBL1175355 | 0.86 | MAPK14 (0.41) | MAPK14CCNKCDK12CA2NPC1 | |
| SCHEMBL15293620 | 0.80 | MAPK14 (0.47) | MAPK14CCNKCDK12CA2APP | |
| SCHEMBL17669425 | 0.79 | MAPK14 (0.45) | MAPK14CCNKCDK12CA2 | |
| SCHEMBL13552055 | 0.79 | MAPK14 (0.45) | MAPK14CCNKCDK12CA2 | |
| SCHEMBL5464799 | 0.78 | MAPK14 (0.53) | MAPK14CCNKCDK12CA2 | |
| SCHEMBL13492104 | 0.78 | MAPK14 (0.53) | MAPK14CCNKCDK12CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2217594-B1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2014-01-08 | — | — | EP | disclosed |
| US-8299086-B2 | Pyrimidine derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-10-30 | — | — | US | disclosed |
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-09-16 | — | — | US | disclosed |
| EP-2217594-A2 | NOVEL PYRIMIDINE DERIVATIVES | Actelion Pharmaceuticals Ltd. (CH) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009057079-A2 | NOVEL PYRIMIDINE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2009-05-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234346-A1 | NOVEL PYRIMIDINE DERIVATIVES | TYMP, TYMS, DPYD | MAPK14 2373/4885CCNK 342/4885CDK12 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.